Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Sosei Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JSS has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: JSS underperformed the German Pharmaceuticals industry which returned 16% over the past year.
Return vs Market: JSS underperformed the German Market which returned 3.9% over the past year.
Price Volatility Vs. Market
How volatile is Sosei Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Sosei Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JSS (€12.4) is trading below our estimate of fair value (€14.25)
Significantly Below Fair Value: JSS is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: JSS is unprofitable, so we can't compare its PE Ratio to the DE Pharmaceuticals industry average.
PE vs Market: JSS is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JSS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: JSS is good value based on its PB Ratio (2.8x) compared to the DE Pharmaceuticals industry average (3.2x).
How is Sosei Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JSS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: JSS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: JSS's is expected to become profitable in the next 3 years.
Revenue vs Market: JSS's revenue (8.1% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: JSS's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JSS's Return on Equity is forecast to be low in 3 years time (5.9%).
How has Sosei Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JSS is currently unprofitable.
Growing Profit Margin: JSS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JSS is unprofitable, and losses have increased over the past 5 years at a rate of -34.2% per year.
Accelerating Growth: Unable to compare JSS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JSS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.8%).
Return on Equity
High ROE: JSS has a negative Return on Equity (-0.79%), as it is currently unprofitable.
How is Sosei Group's financial position?
Financial Position Analysis
Short Term Liabilities: JSS's short term assets (¥18.4B) exceed its short term liabilities (¥1.7B).
Long Term Liabilities: JSS's short term assets (¥18.4B) exceed its long term liabilities (¥8.9B).
Debt to Equity History and Analysis
Debt Level: JSS is debt free.
Reducing Debt: JSS has no debt compared to 5 years ago when its debt to equity ratio was 133.2%.
Debt Coverage: JSS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: JSS has no debt, therefore coverage of interest payments is not a concern.
What is Sosei Group current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JSS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JSS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JSS's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shinichi Tamura (71yo)
Mr. Shinichi Tamura is the founder of Sosei Co. Ltd. and has been its President and Representative Executive Officer since November 2006. Mr. Tamura is the Founder of Sosei Group Corporation and has been i ...
CEO Compensation Analysis
Compensation vs Market: Shinichi's total compensation ($USD1.70M) is about average for companies of similar size in the German market ($USD1.43M).
Compensation vs Earnings: Shinichi's compensation has been consistent with company performance over the past year.
|Executive Vice Chairman||0.33yr||JP¥134.00m||no data|
|Executive Officer||2.08yrs||JP¥101.00m||no data|
|Chief Technology Officer||0.67yr||no data||no data|
|Chief Scientific Officer||0.67yr||no data||no data|
|Vice President of Investor Relations||no data||no data||no data|
|Executive Officer||2.5yrs||no data||no data|
|Vice President of Corporate Strategy & Communications||no data||no data||no data|
|Executive Officer||2.5yrs||no data||no data|
|Executive Officer & Executive VP||1.33yrs||no data||0.00099% ¥10.0k|
Experienced Management: JSS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|Executive Vice Chairman||0.33yr||JP¥134.00m||no data|
|Independent External Director||0.33yr||no data||no data|
|Independent External Director||9.08yrs||no data||0.0071% ¥72.1k|
|External Independent Director||1.33yrs||no data||no data|
|Independent External Director||2.08yrs||no data||0.0063% ¥64.1k|
|Independent External Director||2.08yrs||no data||0.00011% ¥1.1k|
Experienced Board: JSS's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.
Sosei Group Corporation's company bio, employee growth, exchange listings and data sources
- Name: Sosei Group Corporation
- Ticker: JSS
- Exchange: DB
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥122.516b
- Listing Market Cap: JP¥1.014b
- Shares outstanding: 80.50m
- Website: https://soseiheptares.com
Number of Employees
- Sosei Group Corporation
- PMO Hanzomon
- 11th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SOLT.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jul 2004|
|4565||TSE (The Tokyo Stock Exchange)||Yes||Common Shares||JP||JPY||Jul 2004|
|JSS||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jul 2004|
Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; and ORAVI, an oropharyngeal candidiasis. The company’s product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of solid tumors and metastatic castration resistant prostate cancer; HTL0016878, a muscarinic M4 agonist, which is in Phase I clinical trial for the treatment of Alzheimer’s disease; and dual muscarinic M1/M4 agonist, which is in pre-clinical stage for the treatment of Alzheimer’s disease. It also develops HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial for the treatment of certain neurological order; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial for the treatment of endocrine disorders; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage for the treatment of migraine and other severe headaches; GLP-1 antagonist, a potent glucagon-like peptide-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; and GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage for the treatment of intestinal disorders. In addition, the company’s pipeline products include OX-1 antagonist to treat cocaine-use disorders; Apelin agonist for pulmonary arterial hypertension; GPR35 agonist to treat inflammatory bowel disease; H4 antagonist and PAR2 mAb for atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab, PeptiDream Inc., Pfizer, MorphoSys, Genentech, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in Tokyo, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/11 21:19|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.